Rotterdam

• Towards organ preservation and cure via immunotherapy in cutaneous squamous cell carcinoma patients, normally undergoing morbid curative sur … Recruiting
  2024-516152-17-00 4 2025-04-24 Cutaneous squamous cell carcinoma
• Transtympanic sodium thiosulfate to prevent cisplatin-related hearing loss, a randomized controlled multicenter phase III trial; The SOUND t … Recruiting
  2023-503313-30-01 5 2025-04-14 Head and Neck squamous cell carcinoma
• StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial Recruiting
  2024-517343-31-00 6 2025-04-11 Ischemic stroke and transient ischemic attack
• Treatment of ELectroencephalographic STatus epilepticus After cardiopulmonary Resuscitation-2 (TELSTAR-2): a multicenter randomised clinical … Recruiting
  2024-516068-27-01 5 2025-04-10 cardiopulmonary resuscitation
• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Recruiting
  2024-513547-82-00 5 2025-03-11 Transthyretin Amyloidosis
• Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting
  2024-513443-93-00 4 2025-03-10 Recurrent Meningioma without local treatment options (Surgery or Radio
• Melatonin for patients with chronic low back pain - a randomized placebo-controlled trial Recruiting
  2024-514769-20-00 5 2025-03-02 Chronic low back pain
• Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 … Recruiting
  2022-500747-21-00 4 2025-02-27 Geographic Atrophy
• The OxyTUTION Trial Recruiting
  2024-516813-19-00 4 2025-02-26 central diabetes insipidus
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
• Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting
  2024-513853-66-00 5 2025-02-04 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
• A first-in-human, dose escalation and dose expansion study of SAR445877 in adult participants with advanced solid tumors Recruiting
  2023-507141-28-00 7 2025-01-29 Solid tumor
• Pred Forte® versus placebo eye drops in chronic central serous chorioretinopathy trial (PICS trial) Recruiting
  2024-511575-15-00 5 2025-01-29 Central serous chorioretinopathy
• CXCR4-directed [68Ga]Ga-PentixaFor PET/CT vs AVS performance in a diagnoStic randomized Trial Ultimately comparing hypertenSion outcome in p … Recruiting
  2024-512628-12-00 10 2025-01-28 Primary aldosteronism
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
• Exploratory Study of CAPEcitabine pharmacokinetics and hand-foot syndrome in CES1 variant carriers: the ESCAPE study Recruiting
  2024-516788-96-00 6 2025-01-20 Locally advanced or metastatic gastro-intestinal carcinoma
• BuLLSEYE Recruiting
  2024-512950-13-00 11 2025-01-03 Sepsis
• RIO Trial Recruiting
  2024-514564-13-00 4 2025-01-02 HIV
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Recruiting
  2024-511188-26-00 5 2024-12-20 Relapsed/refractory multiple myeloma in patients who have received 1 t
• Safe Stop Trial Melanoma Recruiting
  2024-516937-10-01 5 2024-12-18 Melanoma
• Efficacy of antibiotic treatment for patients with chronic low back pain Recruiting
  2024-515824-35-01 6 2024-12-17 non-specific low back pain
• A clinical study of sacituzumab tirumotecan (sac-TMT) in people with bladder cancer (MK-2870-027) Recruiting
  2024-514983-23-01 9 2024-12-16 Intermediate-risk Non-muscle Invasive Bladder Cancer
• A Phase-2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Enc … Recruiting
  2023-504686-23-00 4 2024-12-10 anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAR encephalit
• Optimizing therapy with n=1-studies: negating the 'nocebo' effect in statin-intolerance Recruiting
  2023-507489-20-00 6 2024-12-10 Statin-intolerance

Showing 265–288 of 818 trials